Direct Antiviral Agents May Obviate the Need for Liver Transplantation for HCV Cirrhosis by the End of the Decade
Surgeries · 23.04.2026 · 7 (2) · 51
DOI: 10.3390/surgeries7020051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgeries, online erschienen am 23.04.2026. Verfasst von Nathanael Haynes und 15 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hepatitis C viral infection (HCV) has historically been a leading indication for liver transplantation (LTx), primarily due to its progression to cirrhosis and hepatocellular carcinoma (HCC). However, the advent of direct-acting antiviral agents (DAAs) over a decade ago has revolutionized HCV treatment, achieving sustained virologic response (SVR) in over 90% of patients and potentially altering LTx indications.
Aim
To investigate the impact of DAAs on HCV-related indications, with or without HCC, and model future trends in LTx indications.
Methods
We retrospectively reviewed 1504 liver transplants performed between 2000 and 2024 at a single center. Patients were categorized into three cohorts: HCV-only, HCC-only, and HCC with HCV co-infection (HCC/HCV). Relative transplant volumes by-year, post-operative outcomes, and HCC recurrence rates were analyzed across pre- and post-DAA eras. ARIMA modeling was employed to project trends in transplant indications through the year 2030.
Results
The proportion of transplants for HCV alone declined by 82.3% from 2015 to 2020, while HCC/HCV transplants decreased by 68.8%. Conversely, the total number of transplants for HCC alone increased during this period, with a modest proportional decrease of 8.3% from 2015 to 2020. ARIMA modeling suggests that by 2030, LTxs for HCV alone may be nearly eliminated. The projected proportion of transplants conducted for HCC alone remains the highest of all three study indications at 4.3%.
Conclusions
DAAs have reduced LTx due to HCV. By 2030, LTx for HCV-related cirrhosis, particularly without HCC, may be obviated. This underscores the need to reevaluate allocation for emerging oncologic indications.
Zitieren
APA
Haynes, N., Cochran, A., Baimas-George, M., Archie, W., Mylarapu, N., Casingal, V., Soto, J., Zamor, P., DeLemos, A., Schmeltzer, P., Zacks, S., Adlakha, N., Denny, R., Russo, M., Eskind, L., & Vrochides, D. (2026). Direct Antiviral Agents May Obviate the Need for Liver Transplantation for HCV Cirrhosis by the End of the Decade. Surgeries, 7(2), 51. https://doi.org/10.3390/surgeries7020051
Vancouver
Haynes N, Cochran A, Baimas-George M, Archie W, Mylarapu N, Casingal V, et al. Direct Antiviral Agents May Obviate the Need for Liver Transplantation for HCV Cirrhosis by the End of the Decade. Surgeries. 2026;7(2):51. doi:10.3390/surgeries7020051
BibTeX
@article{Haynes2026,
author = {Haynes, Nathanael and Cochran, Allyson and Baimas-George, Maria and Archie, William and Mylarapu, Namratha and Casingal, Vincent and Soto, Jose and Zamor, Philippe and DeLemos, Andrew and Schmeltzer, Paul and Zacks, Steven and Adlakha, Natasha and Denny, Roger and Russo, Mark and Eskind, Lon and Vrochides, Dionisios},
title = {Direct Antiviral Agents May Obviate the Need for Liver Transplantation for HCV Cirrhosis by the End of the Decade},
journal = {Surgeries},
year = {2026},
volume = {7},
number = {2},
pages = {51},
doi = {10.3390/surgeries7020051}
}
EUVIMED